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Introduction
Adenosine receptors regulate brain function and may have key roles in neurodegenerative disorders. Adenosine A 2A receptors (A 2A Rs) are highly expressed in inhibitory medium spiny neurons of the striatum and regulate the balance between the direct and indirect neural pathways controlling movement (Schwarzschild et al., 2006) . A 2A R blockers enhance motor function in animal models of Parkinson's disease (PD). Istradefylline, a selective A 2A R blocker, is safe and well-tolerated (Kondo et al., 2015) and approved in Japan for the treatment of PD (Pinna, 2014) .
In animal models, A 2A R blockade or removal ameliorated cognitive dysfunction resulting from acute brain trauma or seizures (Cognato et al., 2010; Ning et al., 2013) . A 2A Rs expressed by neurons or astrocytes also contribute to cognitive deficits in models of Alzheimer's disease (AD) (Cunha et al., 2008; Laurent et al., 2016; Orr et al., 2015; Dall'Igna et al., 2007; Canas et al., 2009; Espinosa et al., 2013; Viana da Silva et al., 2016) . Furthermore, we previously found that A 2A R levels on astrocytes were markedly increased in AD patients, and the increases correlated with disease severity (Orr et al., 2015) . Gene-expression profiling in postmortem human brains revealed that A 2A mRNA levels correlate positively with frontal cortex atrophy in late-onset AD (Zhang et al., 2013) . Moreover, genetic ablation of A 2A Rs in astrocytes enhanced reference memory in mice with or without AD-like plaque pathology (Orr et al., 2015) , but impaired working memory in mice without plaques (Matos et al., 2015) , supporting the notion that astrocytes regulate cognitive functions (Ransom and Ransom, 2012) . These findings also suggest that alterations in A 2A R levels contribute to cognitive deficits in AD. However, it is uncertain what causes the increases in astrocytic A 2A R levels in AD and whether A 2A R antagonists can reduce cognitive deficits in the context of AD-like plaque pathology. Here, we analyzed A 2A R expression in APP transgenic mice with or without plaque pathology and assessed the effects of istradefylline on the behavior of plaque-bearing mice.
Materials and methods

Animals
Mice were housed in the Gladstone animal facility and treated in 
